{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:24:07Z","timestamp":1785284647248,"version":"3.55.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semradonc.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:28:07Z","timestamp":1757514487000},"page":"583-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging Systemic Therapy Considerations for Pancreatic Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Kai-li","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Z.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeha","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2025.07.006_bib0001","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0002","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","article-title":"Pancreatic cancer: A review of epidemiology, trend, and risk factors","volume":"27","author":"Hu","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0003","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0005","series-title":"Cancer Facts & Figures 2025","year":"2025"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hpb.12078","article-title":"2564 resected periampullary adenocarcinomas at a single institution: Trends over three decades","volume":"16","author":"He","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0008","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/SLA.0000000000004093","article-title":"Detection, treatment, and survival of pancreatic cancer recurrence in the Netherlands: A nationwide analysis","volume":"275","author":"Daamen","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101780","article-title":"Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling","volume":"38","author":"Glorieux","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0012","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.3390\/cancers13195028","article-title":"Pancreatic cancer microenvironment and cellular composition: Current understandings and therapeutic approaches","volume":"13","author":"Truong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0013","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0014","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.celrep.2017.04.052","article-title":"The presence of interleukin-13 at pancreatic ADM\/PanIN lesions alters macrophage populations and mediates pancreatic tumorigenesis","volume":"19","author":"Liou","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0015","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0017","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-Induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0018","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0019","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0022","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0023","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","article-title":"Real-time genomic profiling of pancreatic ductal adenocarcinoma: Potential actionability and correlation with clinical phenotype","volume":"23","author":"Lowery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0024","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0026","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0027","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the know your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0028","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0029","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs Gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0031","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0032","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0033","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1007\/s12325-022-02317-9","article-title":"Treatment patterns in US patients receiving first-line and second-line therapy for metastatic pancreatic ductal adenocarcinoma in the real world","volume":"39","author":"King","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0034","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: Early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0035","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","article-title":"Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0036","article-title":"An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer","volume":"5","author":"Ruta","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0037","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","article-title":"Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals Co-expressor phenotypes and extensive intratumoral heterogeneity","volume":"83","author":"Williams","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0038","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 Expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","volume":"26","author":"O'Kane","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0039","article-title":"Tumor mutational burden in real-world patients with pancreatic cancer: Genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0041","doi-asserted-by":"crossref","first-page":"799","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3420","article-title":"Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma","volume":"4","author":"Qian","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0043","article-title":"KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer","volume":"6","author":"Lansbergen","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113497","article-title":"Precision medicine for KRAS wild-type pancreatic adenocarcinomas","volume":"197","author":"Ben-Ammar","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0045","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0046","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0047","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0048","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0049","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0050","volume":"43","author":"Spira","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0051","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0052","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0053","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1021\/acsomega.3c00329","article-title":"Discovery of prodrug of MRTX1133 as an oral therapy for cancers with KRAS(G12D) mutation","volume":"8","author":"Ji","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0054","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","article-title":"608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0055","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0056","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Garrido-Laguna","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0057","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-025-02288-9","article-title":"ADT-1004: A first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma","volume":"24","author":"Bandi","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0058","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1158\/1535-7163.MCT-24-0386","article-title":"Pan-KRAS inhibitors BI-2493 and BI-2865 display potent anti-tumor activity in tumors with KRAS wild-type allele amplification","volume":"24","author":"Tedeschi","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0059","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0061","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0062","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","article-title":"A classical epithelial State drives acute resistance to KRAS inhibition in pancreatic cancer","volume":"14","author":"Singhal","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0063","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1004669","article-title":"Non-genetic adaptive resistance to KRAS(G12C) inhibition: EMT is not the only culprit","volume":"12","author":"Ning","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12672-022-00550-w","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0066","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","article-title":"Dual inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma","volume":"83","author":"Gulay","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0067","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/1535-7163.MCT-23-0251","article-title":"Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C-mutant pancreatic and lung cancers","volume":"22","author":"Khan","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0068","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/1878-0261.13751","article-title":"Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2","volume":"19","author":"Miyazaki","year":"2025","journal-title":"Mol Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0069","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.62347\/DVXL1377","article-title":"Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation","volume":"14","author":"Tajiknia","year":"2024","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0070","doi-asserted-by":"crossref","first-page":"398","DOI":"10.21873\/cgp.20391","article-title":"Targeted therapy for BRAF V600E positive pancreatic adenocarcinoma: Two case reports","volume":"20","author":"Shah","year":"2023","journal-title":"Cancer Genomics Proteom"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0071","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-21-0856","article-title":"KRAS inhibitor resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0072","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: Resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0073","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0074","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0075","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","article-title":"Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma","volume":"10","author":"Muthalagu","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0076","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0077","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0078","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ccell.2022.07.005","article-title":"A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0079","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.devcel.2023.07.025","article-title":"Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8(+) T cells","volume":"58","author":"Mahadevan","year":"2023","journal-title":"Dev Cell"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0080","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: A systematic review and prevalence meta-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0081","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0082","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.21037\/jgo.2019.09.12","article-title":"DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer","volume":"10","author":"Palacio","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0083","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","article-title":"Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX","volume":"24","author":"Sehdev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0084","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0085","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jamcollsurg.2017.12.021","article-title":"BRCA1\/BRCA2 Germline mutation carriers and sporadic pancreatic ductal adenocarcinoma","volume":"226","author":"Blair","year":"2018","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0086","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma","volume":"76","author":"Fogelman","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0087","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0088","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","article-title":"Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer","volume":"70","author":"Tutt","year":"2005","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0091","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: A phase III study of active maintenance Olaparib versus Placebo for Germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0092","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance Rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0093","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of Gemcitabine and Cisplatin with or without Veliparib in patients with Pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0094","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.semcancer.2006.07.004","article-title":"The DNA damage response, immunity and cancer","volume":"16","author":"Gasser","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0095","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0096","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1200\/JCO.2018.78.2425","article-title":"DNA repair deficiency and immunotherapy response","volume":"36","author":"Mouw","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0097","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0098","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: Results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0099","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41416-023-02349-0","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: Results from the dose-expansion stage of a multicentre, open-label, phase I trial","volume":"129","author":"Friedlander","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0100","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular pathways and mechanisms of BRAF in cancer therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0101","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.18632\/oncotarget.2972","article-title":"Molecular landscape of pancreatic cancer: Implications for current clinical trials","volume":"6","author":"Heestand","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0102","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0103","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11523-020-00727-9","article-title":"Molecular targeting of a BRAF mutation in pancreatic ductal adenocarcinoma: Case report and literature review","volume":"15","author":"Seghers","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0104","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.214","article-title":"Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs)","volume":"36","author":"Guan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0105","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in patients with tumors with BRAF(V600E) mutations: Results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: Review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0107","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0046-8177(96)90364-0","article-title":"Immunohistochemical evaluation of HER-2\/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms","volume":"27","author":"Day","year":"1996","journal-title":"Hum Pathol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0108","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/0046-8177(93)90194-L","article-title":"Overexpression of HER2\/neu oncogene in human pancreatic carcinoma","volume":"24","author":"Yamanaka","year":"1993","journal-title":"Hum Pathol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0109","first-page":"1593","article-title":"Role of immunohistochemical identification of her-2\/neu and detection of variability in overexpression in pancreatic carcinoma","volume":"22","author":"Koka","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0110","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"106","author":"Harder","year":"2012","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0111","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0112","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000093497","article-title":"Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique","volume":"23","author":"Bloomston","year":"2006","journal-title":"Dig Surg"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0113","first-page":"3841","article-title":"Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer","volume":"17","author":"Uegaki","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0114","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1200\/JCO.2005.08.043","article-title":"EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment","volume":"23","author":"Marchetti","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0115","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0116","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2004.12.040","article-title":"Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial","volume":"22","author":"Xiong","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(07)70383-2","article-title":"Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial","volume":"9","author":"Cascinu","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0118","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/COC.0b013e31821862fb","article-title":"Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer","volume":"35","author":"Merchan","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0119","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1200\/JCO.22.02630","article-title":"Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2024.01.009","article-title":"Fusion genes in pancreatic tumors","volume":"10","author":"Gkountakos","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00039","article-title":"Entrectinib in TRK and ROS1 fusion-positive metastatic pancreatic cancer","volume":"2","author":"Pishvaian","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0122","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0123","article-title":"Repotrectinib in a patient with NTRK fusion-positive pancreatic carcinoma and congenital Long QT syndrome","volume":"8","author":"Yun","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0124","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0125","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-19-0191","article-title":"NRG1 Gene fusions are recurrent, clinically actionable Gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","volume":"25","author":"Jones","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0126","doi-asserted-by":"crossref","first-page":"555","DOI":"10.6004\/jnccn.2017.0058","article-title":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","volume":"15","author":"Singhi","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0127","article-title":"Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RETfusion\u2013positive solid tumors","volume":"39","author":"Subbiah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0128","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0129","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.6004\/jnccn.2022.7039","article-title":"Exceptional response to Erdafitinib in FGFR2-mutated metastatic pancreatic ductal adenocarcinoma","volume":"20","author":"Ng","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0130","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3390\/cancers13133119","article-title":"Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: Systematic review and still-open questions","volume":"13","author":"Lawlor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0131","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0133","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0134","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of Dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: A nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0136","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0137","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0138","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2008.03.056","article-title":"Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer","volume":"268","author":"Loos","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0139","doi-asserted-by":"crossref","first-page":"71198","DOI":"10.18632\/oncotarget.11685","article-title":"Prognostic value of PDL1 expression in pancreatic cancer","volume":"7","author":"Birnbaum","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0140","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0141","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without Tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0142","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0143","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0144","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cells13181558","article-title":"Fighting pancreatic cancer with a vaccine-based winning combination: Hope or reality?","volume":"13","author":"Brugiapaglia","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0145","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.3390\/curroncol31090361","article-title":"Developing vaccines in pancreatic adenocarcinoma: Trials and tribulations","volume":"31","author":"Phan","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0146","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","article-title":"Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation","volume":"19","author":"Jaffee","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0147","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0148","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2024.10.039","volume":"121","author":"Hill","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0149","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122092","article-title":"T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma","volume":"3","author":"Hopkins","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0150","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0151","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0152","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with Ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0153","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","article-title":"Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant Vaccine in patients with resectable pancreatic adenocarcinoma","volume":"27","author":"Zheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0154","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674565","article-title":"Tertiary lymphoid structures as a predictive biomarker of response to cancer immunotherapies","volume":"12","author":"Tr\u00fcb","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0155","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","article-title":"Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures","volume":"26","author":"Dieu-Nosjean","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0156","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","article-title":"Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0157","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3390\/cancers17071246","article-title":"Immune-based strategies for pancreatic cancer in the adjuvant setting","volume":"17","author":"Liang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0158","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0159","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0160","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0161","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT036","article-title":"Abstract CT036: Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab\/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study","volume":"83","author":"Haldar","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0162","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122857","article-title":"Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer","volume":"3","author":"Kinkead","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0163","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","article-title":"Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0164","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: Chimeric Antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0165","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.omto.2022.01.010","article-title":"The next wave of cellular immunotherapies in pancreatic cancer","volume":"24","author":"Yeo","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0166","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/cells13010101","article-title":"Chimeric antigen receptor T cell therapy for pancreatic cancer: A review of current evidence","volume":"13","author":"Czaplicka","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0167","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216462","article-title":"Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles","volume":"579","author":"Kumar","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0168","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3892\/ol.2021.12908","article-title":"Application of natural killer cells in pancreatic cancer","volume":"22","author":"Peng","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0169","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0170","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-022-05351-1","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0171","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cancers10020034","article-title":"Extracellular influences: Molecular subclasses and the microenvironment in pancreatic cancer","volume":"10","author":"Veenstra","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0172","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-cancerbio-061421-035400","article-title":"Cancer-associated fibroblasts: Lessons from pancreatic Cancer","volume":"7","author":"Sherman","year":"2023","journal-title":"Annu Rev Cancer Biol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0173","first-page":"1044","article-title":"Medical biology of cancer-associated fibroblasts in pancreatic cancer","volume":"12","author":"Morgan","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0174","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","article-title":"Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response","volume":"16","author":"Song","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0176","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0177","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, Pembrolizumab, and Gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I dose escalation and expansion study","volume":"28","author":"Wang-Gillam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0178","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16337","article-title":"Phase 1b\/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis","volume":"42","author":"Burns","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0179","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0180","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.23.02314","article-title":"Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: A pooled analysis of two early-phase trials","volume":"42","author":"Qi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0181","unstructured":"FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. FDA. October 18, 2024. Accessed October 18, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma."},{"key":"10.1016\/j.semradonc.2025.07.006_bib0182","article-title":"Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2\u2013positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study","volume":"41","author":"Park","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0183","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS765","article-title":"A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas","volume":"41","author":"Overman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0184","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","article-title":"Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis","volume":"23","author":"Oweira","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0185","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1200\/JCO.24.00081","article-title":"Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): A multicenter, randomized phase II trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0186","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3511","article-title":"CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC)","volume":"38","author":"Hong","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.006_bib0187","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS845","article-title":"MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors","volume":"43","author":"Lakhani","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:10:37Z","timestamp":1760227837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":187,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1053429625000621"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.006","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Systemic Therapy Considerations for Pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}